Carter Gould

Obviously, you raised the guide there. Should we think about that being primarily driven by U.S. or OUS

Wanted to get a sense understanding of your expectations and flexibility, if need be to take actions outside the US

Are you taking actions or advocating either on your own or in conjunction with peers to address persistent unlawful compounding?

IP is under attack across the industry from multiple sources, but most notably compounding

the extent to which uncertainty around tariffs, FDA, drug pricing environment are sort of stage gates

Is it fair to assume those comments are anchoring on aperture adherence around 50% still

we've seen pretty volatile scripts over here the past couple of weeks. And I guess my question is, are the TRx that we're seeing reflective of what you're seeing

there have been a number of cuts across HHS, CDC to start the year across various teams, divisions. Raising uncertainty around potential disruptions

anything you can share there around if you think potential MFN legislation is a priority or possibility in the coming balance of the year?

can this reach your targets if it ultimately requires every 4-week dosing? Or put differently, are there reasons you have conviction

how does Merck think about the importance and speed it may need to pursue combinations on the back of those data

I wanted to ask you around your confidence in ultimately hitting on OS in the 022 study

should investors have any expectation around a comprehensive deal that addresses the President's objectives across MFN and tariffs

should we think about that as more of a convenience play sort of with the co-administration

can you help us think about if there's been -- if you've delivered any matching funds yet